Skip to main content
. 2021 Apr 30;7(18):eabf7390. doi: 10.1126/sciadv.abf7390

Fig. 4. Enhanced delivery of siRNA into the SHH-activated medulloblastoma tumor using MB-FUS and cationic LPH:SMO-siRNA.

Fig. 4

(A) In vivo experiment setup using a custom-built USgFUS system (left). Schematic graph is created with BioRender.com. Representative contrast-enhanced T2-weighted MR images of medulloblastoma tumor–bearing mice (right, top) and contrast-enhanced T1-weighted MR images of healthy mice after FUS BBB disruption (BBBD) targeted at the location of medulloblastoma tumor (right, bottom). (B) Harmonic emission from the MB-mediated BTB disruption using FUS. (C) Quantification of the acoustic emissions. (D) In vivo experimental protocol for the delivery of cationic LPH:SMO-siRNA in a medulloblastoma mouse tumor model. (E) Representative fluorescent microscopy data of LPH accumulation in tumor for non–FUS-treated group (left) and FUS-treated group (right). (F) Quantification of the LPH accumulation in tumor with and without FUS at 30 hours after treatment (9.4-fold, P = 0.0472). (G) Representative fluorescent data of FISH assay on non–MB-FUS group (top) and MB-FUS group (bottom). Plots show means ± SEM (N = 3). P values were determined by unpaired t tests. n.s., no statistical significance; *P ≤ 0.05; ****P ≤ 0.0001.